Cargando…
Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.
Autores principales: | Nagashima, Kana, Kikuchi, Shohei, Iyama, Satoshi, Fujita, Chisa, Goto, Akari, Horiguchi, Hiroto, Kobune, Masayoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069848/ https://www.ncbi.nlm.nih.gov/pubmed/32185037 http://dx.doi.org/10.1002/ccr3.2688 |
Ejemplares similares
-
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019) -
Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020) -
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015) -
Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021) -
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
por: Abramson, Jeremy S., et al.
Publicado: (2022)